Close this search box.

Meet the Team

Kayvon Namvar

Contact Kayvon

Kayvon Namvar


Kayvon Namvar brings years of experience to the firm providing forecasting, valuation, opinion, litigation support and transaction advisory support services to the life sciences, entertainment and media, and technology industries, among others.

He has also worked extensively with law firms, banks, venture capital firms, and private equity firms in a variety of settings. Mr. Namvar has spent his career working with clients in communicating the value of intangible assets and companies under the scrutiny of capital markets, auditors, tax authorities, and lawyers.

In the life sciences industry, Mr. Namvar has developed dynamic patient-flow and financial models to facilitate the forecasting and valuation of biopharmaceutical products, companies, complex securities and royalty interests for transaction, bankruptcy, tax and accounting oriented purposes. He has worked with companies ranging from large, publicly traded entities, to small, venture capital-backed organizations.

With respect to technology, Mr. Namvar has been involved in the forecasting and valuation of patent portfolios, as well as assisting in the development of long-term strategic plans and options for companies developing and commercializing innovative intellectual property.

Prior to joining RNA Capital Advisors, Mr. Namvar was a director in the Valuation & Financial Advisory Services group within the Corporate Finance/Restructuring division of FTI Consulting, Inc. Mr. Namvar joined FTI via the acquisition of his predecessor firm, The Salter Group, LLC, a leading independent financial and strategic advisory firm serving multiple industry segments.

Mr. Namvar holds a B.S. in Business Administration with a concentration in Corporate Finance from the University of Southern California (USC). Mr. Namvar has been a guest lecturer and presenter on corporate finance subjects at his alma mater.

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.